DiscoverIDBR Infectious Disease Board ReviewEvaluating risk of HIV - Trip Gulick, MD
Evaluating risk of HIV - Trip Gulick, MD

Evaluating risk of HIV - Trip Gulick, MD

Update: 2024-05-27
Share

Description

A 62-year-old man with a history of hypertension has taken HIV PrEP with tenofovir DF/emtricitabine for 5


years.


His baseline creatinine clearance was 85 cc/min, but this has trended down with his latest creatinine


clearance 55 cc/min (repeated at 60 cc/min).


He is in a monogamous relationship with his partner who has HIV and is taking a bictegravir-based regimen


with HIV RNA <20 for years.


How would you manage his PrEP?


A. Continue tenofovir DF/emtricitabine, follow creatinine clearance monthly


B. Change to tenofovir AF/emtricitabine


C. Change to injectable cabotegravir every other month


D. Stop PrEP

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Evaluating risk of HIV - Trip Gulick, MD

Evaluating risk of HIV - Trip Gulick, MD

John Bennett, MD / Henry Masur, MD